EP1988893A2 - Mittels cyclodextrin stabilisierte desloratadine enthaltende formulierung - Google Patents

Mittels cyclodextrin stabilisierte desloratadine enthaltende formulierung

Info

Publication number
EP1988893A2
EP1988893A2 EP07733895A EP07733895A EP1988893A2 EP 1988893 A2 EP1988893 A2 EP 1988893A2 EP 07733895 A EP07733895 A EP 07733895A EP 07733895 A EP07733895 A EP 07733895A EP 1988893 A2 EP1988893 A2 EP 1988893A2
Authority
EP
European Patent Office
Prior art keywords
cyclodextrin
oral pharmaceutical
desloratadine
dosage form
stable oral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07733895A
Other languages
English (en)
French (fr)
Other versions
EP1988893A4 (de
Inventor
Mathivanan Natarajan
Sreekanth Joginapalli
Praveen Reddy Billa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Orchid Pharma Ltd
Original Assignee
Orchid Chemicals and Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orchid Chemicals and Pharmaceuticals Ltd filed Critical Orchid Chemicals and Pharmaceuticals Ltd
Publication of EP1988893A2 publication Critical patent/EP1988893A2/de
Publication of EP1988893A4 publication Critical patent/EP1988893A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins

Definitions

  • the present invention relates to a stable oral pharmaceutical composition. More particularly the invention relates to a stable oral pharmaceutical composition containing desloratadine and a process for preparing the stable oral pharmaceutical composition.
  • Desloratadine a metabolic derivative of loratadine is a long acting tricyclic antihistamine with selective Hi -receptor antagonist activity. Desloratadine is chemically 8-chloro-6,l 1-dihydro-l l-(4-piperidylidene)-5H-benzo[5,6]-cyclohepta 1,2- b]pyridine.
  • U.S. Patent No. 4,659,716 discloses desloratadine possessing antihistaminic properties with substantially no sedative properties.
  • Maillard reaction is a nonenzymatic chemical reaction involving condensation of an amino group and a reducing group.
  • Desloratadine is a secondary amine, which makes it susceptible to maillard reaction when formulated with wide variety of excipients commonly used in oral formulations resulting in degradation. This maillard type degradation is pronounced in the presence of water and/or elevated temperature.
  • N-formyl desloratadine has been reported to be the major decomposition product of desloratadine.
  • U.S. Patent No. 6,100,274 discloses that desloratadine discolors and decomposes in the presence acidic excipients and avoiding the use of acidic excipients and combining desloratadine with acceptable carrier medium comprising a basic salt substantially solve that problem.
  • Published application 2002/0123054 describes various methods of providing stable desloratadine formulation including providing desloratadine formulation free of reactive excipients such as lactose or other mono- or di- saccharides, use of anhydrous desloratadine, use of desloratadine with increased particle size, providing non hygroscopic desloratadine containing formulations, coating desloratadine with a protective agent.
  • a stable oral pharmaceutical composition comprising desloratadine, cyclodextrin as stabilizer and pharmaceutically acceptable excipients.
  • an embodiment of the stable oral pharmaceutical composition includes one or more of the following features.
  • the cyclodextrin is selected from alpha cyclodextrin, beta cyclodextrin, gamma cyclodextrin, their derivatives or mixtures thereof.
  • beta cyclodextrin is used.
  • the ratio of desloratadine to cyclodextrin is from about 1 :5 to about 1:25, preferably from about 1 :10 to about 1:15.
  • the stable oral pharmaceutical composition contains less than 0.5 % w/w of N- formyl desloratadine when stored at 40° C and 75% relative humidity over an extended period of time.
  • the stable oral pharmaceutical composition does not undergo discoloration when stored at 40° C and 75% relative humidity over an extended period of time.
  • the oral pharmaceutical composition is stable even in the presence of excipients, which are reactive with desloratadine, wherein the reactive excipient may be lactose and /or other mono- or disaccharides.
  • a process for preparing stable oral pharmaceutical dosage form comprising a) forming a mixture of desloratadine, cyclodextrin with one or more pharmaceutical excipients b) processing the mixture into an oral dosage form.
  • Embodiments of process may include one or more of the features as described above.
  • the cyclodextrin may be alpha cyclodextrin, beta cyclodextrin, gamma cyclodextrin, their derivatives or mixtures thereof, preferably beta cyclodextrin.
  • the ratio of desloratadine to cyclodextrin is from about 1:5 to about 1:25, preferably from about 1:10 to about 1:15.
  • the stable oral pharmaceutical dosage form of the process contains less than 0.5
  • % w/w of N-formyl desloratadine when stored at 40° C and 75% relative humidity over an extended period of time.
  • the stable oral pharmaceutical composition does not undergo discoloration when stored at 40° C and 75% relative humidity over an extended period of time.
  • the stable oral pharmaceutical dosage form of the process is stable even in the presence of excipients, which are reactive with desloratadine.
  • the reactive excipient may be lactose and /or other mono- or disaccharides.
  • forming of mixture involves wet granulation, dry granulation or direct compression.
  • the mixture is processed into oral dosage forms like tablet, capsules or pellets.
  • the present invention provides a stable pharmaceutical composition
  • a stable pharmaceutical composition comprising descarbonylethoxyloratadine (Desloratadine), cyclodextrin as stabilizer and pharmaceutically acceptable excipients.
  • compositions of the present invention comprise desloratadine in an anti allergically effective amount.
  • the anti allergic effective amount of desloratadine in the pharmaceutical compositions of the present invention is from about 0.1 mg to about 15 mg, preferably from about 1 mg to about 10 mg.
  • Cyclodextrins have been used to enhance the solubility and stability of drugs in aqueous solution.
  • Passington, in chemistry of England, May 1987, page 457 has reported that beta cyclodextrin complexes or inclusion compounds enhance the solubility of prostaglandins, steroid hormones, diuretics and barbiturates and stabilize the hydrolysis of aspirin, atropine, and procaine, stabilize the oxidation of chlorpromazine and epinephrine, stabilize the dehydration of prostaglandin E groups.
  • Other reference, which provides the characteristics of cyclodextrin and describes its use in pharmaceutical compositions include the following "Cyclodextrin Chemistry" by M. L.
  • compositions comprising desloratadine are however accompanied by such drawbacks that they are unstable when stored for a long periods of time.
  • Desloratadine compositions are known to be susceptible to chemical and physical instability. Desloratadine chemically degrades to N-formyl deslortadine impurity. Desloratadine composition is also known to undergo discoloration in the presence of wide variety of conventional excipients commonly used in oral formulations.
  • compositions comprising desloratadine can be obtained using cyclodextrin as stabilizer, wherein cyclodextrin is used in amounts such that it prevents discoloration of the composition and/or minimizes the degradation of desloratadine to its N-formyl desloratadine
  • the pharmaceutical composition of the instant invention in addition to providing stability provides freedom for the use of conventional excipients and process.
  • the compositions of the present invention in the presence of cyclodextrin are found to be stable when stored at 40° C and 75% relative humidity as represented in Example 1.
  • Example 1 the formation of N-formyl desloratadine is significantly minimized and there is no color change when compared to pharmaceutical compositions without cyclodextrin (Comparative Example).
  • Cyclodextrin includes any of the known cyclodextrins such as unsubstituted cyclodextrins containing from six to twelve glucose units, especially alpha-cyclodextrin, beta-cyclodextrin, gamma-cyclodextrin and/or their derivatives and/or mixtures thereof. Unsubstituted cyclodextrins are preferred and more preferably beta-cyclodextrin is preferred.
  • the ratio of desloratadine to cyclodextrin in the composition may range from about 1:5 to about 1 :25, preferably about 1 :10 to about 1 :15.
  • the pharmaceutically acceptable excipients of the present invention may be solids or liquids, that include but not limited to diluents, binders, disintegrating agents, solubilizers, lubricants, glidants, suspending agents, coating aids, encapsulating materials.
  • the diluents or fillers may be one ore more selected from lactose, and other mono- or disaccharides, cellulose derivatives like microcrystalline cellulose.
  • the binders may be one or more selected from crospovidone, starch or starch derivatives and cellulose derivatives.
  • the disintegrant may be one or more selected from crospovidone, croscarmellose sodium, starch, starch derivatives or cellulose polymers.
  • the lubricant may be one or more selected from talc, colloidal silicon dioxide, magnesium stearate, stearic acid, stearic acid salts and glycols.
  • the glidants include colloidal silicon dioxide, talc and the like.
  • the pharmaceutical composition of the present invention can be formulated into oral dosage forms, in the form of tablets, capsules, pellets, dispersible granules and powder preferably in the form of tablet.
  • tablette used here encompasses compressed dosage formulations of all shapes and sizes whether coated or uncoated.
  • the pharmaceutical composition of the present invention may also contain one or more additional formulation ingredients known in the pharmaceutical formulation art, such excipients include but not limited to flavoring agents, anti oxidants, sweeteners, wetting agents, coloring agents, buffering agents, preservatives and mixtures thereof.
  • the pharmaceutical composition of the present invention can be processed into oral dosage forms by conventional process of wet granulation, dry granulation or direct compression.
  • wet granulation the drug along with cyclodextrin and various excipients selected from a diluent, a binder, disintegrant and optionally other conventional excipients selected from antioxidants, flavors, sweeteners, preservatives, buffering agents are mixed, granulated, followed by screening and drying of the damp mass.
  • the dried granules are further processed into desired oral dosage form.
  • Dry granulation cane be done by slugging which involves blending the drug with cyclodextrin and excipients selected from a diluent, a binder, disintegrant and optionally other conventional excipients selected from antioxidants, flavors, sweeteners, preservatives, buffering agents, followed by slugging, dry screening, compression or roller compaction and processed into desired oral dosage form such as tablets, capsules or pellets.
  • slugging involves blending the drug with cyclodextrin and excipients selected from a diluent, a binder, disintegrant and optionally other conventional excipients selected from antioxidants, flavors, sweeteners, preservatives, buffering agents, followed by slugging, dry screening, compression or roller compaction and processed into desired oral dosage form such as tablets, capsules or pellets.
  • the composition can be prepared by direct compression, the process comprising; forming a blend of desloratadine and cyclodextrin with excipients by mixing with a diluent, a binder, a disintegrant, and optionally one. or more conventional excipients selected from antioxidants, flavors, sweeteners, preservatives and buffering agents.
  • the above blend can be further processed into the desired oral dosage forms such as tablets, capsules or pellets.
  • the resulting tablets optionally may be coated with a suitable coating composition.
  • the pharmaceutical composition of the present invention represents a stable formulation of desloratadine, which can be used for the relief of the nasal and non-nasal symptoms of allergic rhinitis (seasonal and perennial) and also for the symptomatic relief of pruritus, in patients with chronic idiopathic urticaria.
  • Desloratadine, ⁇ -Cyclodextrin, Cornstarch, a portion of Low substituted Hydroxy Propyl Cellulose, a portion of Colloidal silicon dioxide were mixed and granulated with Butylated Hydroxy Anisole solution (Butylated Hydroxy Anisole dissolved in Isopropyl Alcohol and water). The resulting granules were dried, mixed with remaining portion of Low substituted Hydroxy Propyl Cellulose, Croscarmellose sodium and lubricated with remaining portion of Colloidal silicon dioxide, Magnesium stearate. The resulting mixture is compressed in to tablets and coated with aqueous dispersion of Opadry Blue.
  • Butylated Hydroxy Anisole solution (Butylated Hydroxy Anisole dissolved in Isopropyl Alcohol) to ⁇ -cyclodextrin and dried.
  • the resultant is mixed with Desloratadine, low substituted Hydroxy Propyl Cellulose, Colloidal silicon dioxide and talc.
  • the resulting mixture is compressed into tablets and coated with aqueous dispersion of Opadry blue.
  • desloratadine was formulated with a reactive excipient such as lactose.
  • Desloratadine, ⁇ -Cyclodextrin, Cornstarch, a portion of Low substituted Hydroxy Propyl Cellulose, a portion of Colloidal silicon dioxide were mixed and granulated with Butylated Hydroxy Anisole solution (Butylated Hydroxy Anisole dissolved in Isopropyl Alcohol and water). The resulting granules were dried, mixed with remaining portion of Low substituted Hydroxy Propyl Cellulose, Croscarmellose sodium, Lactose Monohydrate and lubricated with remaining portion of Colloidal silicon dioxide, Magnesium stearate. The resulting mixture is compressed in to tablets and coated with aqueous dispersion of Opadry Blue.
  • desloratadine was formulated without cyclodextrin.
  • Butylated Hydroxy Anisole solution (Butylated Hydroxy Anisole dissolved in Isopropyl Alcohol) to Microcyrstalline cellulose and dried.
  • the resultant is mixed with Desloratadine, low substituted Hydroxy Propyl Cellulose, Colloidal silicon dioxide and talc.
  • the resulting mixture is compressed into tablets and coated with aqueous dispersion of Opadry blue.
  • compositions of desloratadine can be achieved by formulating desloratadine with cyclodextrin.
  • the compositions of desloratadine of the present invention are stable even in the presence of reactive excipients thereby offering freedom for selecting excipients from a wide range of available excipients.
EP07733895A 2006-02-22 2007-02-19 Mittels cyclodextrin stabilisierte desloratadine enthaltende formulierung Withdrawn EP1988893A4 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN289CH2006 2006-02-22
PCT/IB2007/000385 WO2007096733A2 (en) 2006-02-22 2007-02-19 Desloratadine-containing formulation stabilized with cyclodextrin

Publications (2)

Publication Number Publication Date
EP1988893A2 true EP1988893A2 (de) 2008-11-12
EP1988893A4 EP1988893A4 (de) 2010-05-26

Family

ID=38437741

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07733895A Withdrawn EP1988893A4 (de) 2006-02-22 2007-02-19 Mittels cyclodextrin stabilisierte desloratadine enthaltende formulierung

Country Status (2)

Country Link
EP (1) EP1988893A4 (de)
WO (1) WO2007096733A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2269586B1 (de) 2009-07-01 2011-09-21 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmazeutische Zusammensetzung mit Desloratadin
CN102697711B (zh) * 2012-05-24 2013-10-30 广州新济药业科技有限公司 地氯雷他定口服液体制剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1110543A2 (de) * 1999-12-20 2001-06-27 Schering Corporation Orale Dosiszusammensetzung mit verlängerter Freigabe
WO2005065047A2 (en) * 2003-12-23 2005-07-21 Sun Pharmaceutical Industries Limited Stable oral composition containing desloratadine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003264859A1 (en) * 2001-12-21 2003-12-19 Sampad Bhattacharya Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor
DE10332314B4 (de) * 2003-07-16 2006-10-26 Infineon Technologies Ag Halbleiterspeicher mit kurzer effektiver Wortleitungszykluszeit sowie Verfahren zum Lesen von Daten aus einem derartigen Halbleiterspeicher
JP2005053825A (ja) * 2003-08-04 2005-03-03 Nidek Co Ltd 点眼点鼻用組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1110543A2 (de) * 1999-12-20 2001-06-27 Schering Corporation Orale Dosiszusammensetzung mit verlängerter Freigabe
WO2005065047A2 (en) * 2003-12-23 2005-07-21 Sun Pharmaceutical Industries Limited Stable oral composition containing desloratadine

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2007096733A2 *

Also Published As

Publication number Publication date
EP1988893A4 (de) 2010-05-26
WO2007096733A3 (en) 2007-11-08
WO2007096733A2 (en) 2007-08-30

Similar Documents

Publication Publication Date Title
EP1720531B1 (de) Neue zusammensetzungen mit chinolin-verbindungen
EP1818057B1 (de) Stabile pharmazeutische Zubereitungen von Montelukast-Natrium
US8314124B2 (en) Crystalline salts of quinoline compounds and methods for preparing them
US20050042285A1 (en) Stabilized composition comprising a benzimidazole type compound
EP2068835A2 (de) Imatinib-zusammensetzungen
HU229213B1 (en) Method for stabilizing benzimidazole compounds
KR101479824B1 (ko) 용출 안정성 제제
US20100028425A1 (en) Pharmaceutical composition of atovaquone
JP3586471B2 (ja) トラセミド含有医薬組成物
EP3560482B1 (de) Neuartiges präparat mit benzimidazolderivat
WO2016097011A1 (en) Pharmaceutical composition comprising amorphous nilotinib
KR20200078498A (ko) 레날리도마이드 즉시 방출 제형
JP2004339198A (ja) 非水和キノリンカルボン酸を含有する非吸湿性薬剤組成物
WO2007096733A2 (en) Desloratadine-containing formulation stabilized with cyclodextrin
KR20110092804A (ko) 피타바스타틴 칼슘염을 함유하는 약학 조성물
KR100990223B1 (ko) 세프디니르의 용출속도를 개선한 약제학적 조성물
WO2007134845A2 (en) Olanzapine pharmaceutical composition
EP3505158A1 (de) Pharmazeutische zubereitung enthalten pharmazeutisch akzeptable lenalidomid-säure-salze
US20100003319A1 (en) Raloxifene immediate release tablets
US20080118555A1 (en) Stable pharmaceutical composition containing desloratadine
JP2022007461A (ja) トルバプタン含有口腔内崩壊錠
US5591766A (en) Solid oral formulations of pyridone carboxylic acids
TW592728B (en) A fast-dissolving pharmaceutical composition
EP2520300A1 (de) Pharmazeutische zusammensetzung zur oralen verabreichung
TW201808296A (zh) 含有胺甲蝶呤之膜衣錠

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080820

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20100423

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100901